Published on 22/12/2025
Managing Re-Consent for Participants Turning 18 in Pediatric Trials
In pediatric clinical trials, participants initially provide assent, while legal guardians give informed consent. However, when a participant reaches the age of majority—typically 18 years—they must provide their own informed consent to continue in the trial. This tutorial provides a step-by-step guide for ethically managing re-consent for participants turning 18 during ongoing clinical studies, aligning with CDSCO, USFDA, and EMA regulations.
Why Re-Consent Is Required at Age 18:
- Legal guardianship ends at the age of majority
- Ethical principles require voluntary consent from capable adults
- Failure to re-consent may invalidate continued data collection
- Regulatory audits require documentation of participant autonomy
Applicable Guidelines:
- ICH E6(R3): Requires re-consent when a participant’s legal capacity changes
- 21 CFR 50 Subpart D: Emphasizes the rights of children and their legal representatives
- CDSCO Guidelines: Mandate audio-visual recording and proper documentation of consent in India
Step-by-Step Process for Re-Consenting Participants at Age 18:
Step 1: Establish SOPs and Consent Tracking
- Create an SOP for re-consenting minors reaching adulthood (available templates at Pharma SOPs)
- Maintain a tracker with participant birthdates and upcoming 18th birthdays
- Set reminders 30–60 days before expected re-consent date
Step 2: Prepare an
- Update the ICF to reflect the participant as the decision-maker
- Use adult-centric language and remove guardian references
- Clarify new legal responsibilities of the participant
Step 3: Ethics Committee/IRB Review
- Submit the re-consent ICF as a protocol amendment or planned document
- Provide rationale and expected participant count turning 18
- Include strategies for missed or delayed re-consents
Step 4: Conduct the Re-Consent Process
- Engage the participant in a private session, without guardians
- Explain the ongoing nature of the trial and their new consent role
- Allow questions and ensure understanding through teach-back methods
- Obtain dated signature and update source documents accordingly
Important Considerations for Ethical Compliance:
| Factor | Recommendation |
|---|---|
| Timing | Obtain re-consent within 30 days of 18th birthday |
| Documentation | Retain both original and re-consent forms in site file |
| Comprehension | Assess understanding using simple checklists or quizzes |
| Training | Train staff to handle sensitive re-consent discussions |
How eConsent Can Support This Transition:
- Send automated alerts near 18th birthday milestones
- Deliver re-consent forms remotely with digital signature options
- Maintain a complete audit trail of participant transitions
- Improve comprehension using visual and multimedia formats
Real-World Example:
In a pediatric epilepsy trial, 22 participants turned 18 during the 2-year follow-up. The sponsor had pre-approved adult ICFs ready, and site coordinators obtained re-consent during the next study visit. All forms were tracked in the TMF and verified during the GMP audit process, with zero findings related to re-consent.
Best Practices:
- Prepare adult ICFs at trial start for anticipated re-consent
- Develop a birthday milestone tracker linked to EDC
- Assign re-consent responsibilities to a specific site role (e.g., study nurse)
- Maintain open communication with participants approaching 18
- Log discussions in source notes and Case Report Forms (CRFs)
Common Pitfalls and Solutions:
- Missed re-consents: Use automated trackers to notify study staff
- Participant confusion: Provide educational handouts about re-consent
- Incomplete forms: Review each form before filing in ISF
FAQs Around Re-Consent at Age of Majority:
Is assent sufficient if the participant does not object?
No. At 18, assent is no longer valid. The individual must give legally effective consent.
What if the participant turns 18 between visits?
Obtain re-consent at the next scheduled visit or remotely using eConsent platforms.
Is re-consent needed for observational studies?
Yes, any data collection past age 18 requires direct adult consent unless waived by IRB.
Conclusion:
Re-consenting participants who turn 18 is not just a regulatory requirement—it’s a reaffirmation of ethical responsibility and participant autonomy. By planning ahead, maintaining thorough documentation, and leveraging digital tools, sponsors and sites can ensure seamless transitions from minor to adult consent without disrupting trial integrity. For trials involving long-term follow-ups or extensions, this process is indispensable and should be built into the trial design from day one.